Revenue segments as reported by the company.

Product sales

Royalty, contract and other revenues

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and development

Acquired in-process research and development expenses

Selling, general and administrative

In-process research and development impairment

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Gilead Sciences

Gilead Sciences, Inc. is a biopharmaceutical company, which engages in the research, development, and commercialization of medicines in areas of unmet medical need. The firm's primary areas of focus include human immunodeficiency virus, acquired immunodeficiency syndrome, liver diseases, hematology, oncology, and inflammation and respiratory diseases. It offers antiviral products under Harvoni, Genvoya, Epclusa, Truvada, Atripla, Descovy, Stribild, Viread, Odefsey, Complera/Eviplera, Sovaldi, and Vosevi brands. The company was founded by Michael L. Riordan on June 22, 1987 and is headquartered in Foster City, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Gilead Sciences reports robust earnings, eyes pipeline opportunities for growth

Gilead Sciences delivered strong financial performance in Q4 2022, driven by growth in key product sales. Despite facing challenges in the HIV market for Q1 2023, the company remains focused on leveraging opportunities in its pipeline and strategic investments.

Gilead reports strong Q1 sales, focuses on pipeline growth

Gilead Sciences delivered strong sales driven by key products in Q1 2023.
While facing challenges like lower Veklury sales, Gilead maintains revenue guidance.
The company's strengths lie in its pipeline, successful products, and manufacturing capabilities.
Opportunities in new indications and therapies position Gilead for future growth.

Gilead Sciences reports robust Q2 performance and eyes future growth

Gilead Sciences had a strong quarter with growth in sales and positive pipeline updates.
Trodelvy's performance in different markets and potential Medicare coverage are key highlights.
Challenges include unsuccessful trials and addressing revenue aspirations.
Opportunities lie in expanding BD activities and exploring cell therapy beyond oncology.

Gilead Sciences reports robust Q3 performance amidst market challenges

Gilead Sciences demonstrated strong performance in Q3 2023, driven by growth in base business, oncology, and HIV segments.
While facing challenges such as declining Veklury sales and barriers to CART therapy uptake, Gilead is actively addressing opportunities for growth and market expansion.
The company's strengths lie in robust product sales, particularly in Biktarvy and Trodelvy, with a focus on innovation and strategic positioning in key therapeutic areas.
Overall, Gilead's performance reflects resilience and strategic planning amidst evolving market dynamics and competitive landscapes.

Gilead Sciences reports strong 2023 performance, eyes transformative therapies

Gilead Sciences showcased solid performance in 2023 with notable growth in key product sales areas, despite facing challenges in certain clinical trials. The company's strengths lie in its diverse portfolio, pipeline innovation, and commitment to delivering transformative therapies. With a focus on addressing HIV, oncology, and inflammation, Gilead is well-positioned for future growth and success.

Gilead Sciences reports robust Q1 performance and eyes future growth

Gilead Sciences delivered strong Q1 results driven by oncology and HIV product sales.
Challenges include IP R&D charge from Sema Bay acquisition and competitive market dynamics.
Opportunities lie in expanding cell therapy leadership, advancing HIV pipeline, and upcoming pipeline updates.
Overall, Gilead remains focused on growth through innovation and strategic portfolio advancements.

Gilead Sciences reports robust Q3 performance and eyes market expansion

Gilead Sciences' Q3 performance reflects strong revenue growth and market leadership in key segments, supported by successful product launches and strategic initiatives.
The company's focus on innovation, patient-centric approaches, and market expansion bodes well for future growth and competitive positioning.
While challenges in maintaining growth and managing expenses exist, Gilead's proactive stance on addressing market needs and leveraging opportunities positions it for continued success.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

The only FDA-approved treatment for COVID-19 added $873 million in the third quarter.

Gilead Sales Up 18% in Q3, Thanks to Coronavirus Treatment Remdesivir

Remdesivir generated $873 million in sales during the third quarter, mostly in the U.S., the company said.

Gilead's revenue rises 17% driven by sales of coronavirus treatment remdesivir

Amgen

Amgen Inc. (NASDAQ: AMGN) and Gilead Sciences Inc.

These Two Major Biotechs Are Bouncing Back With Q3 Results

Gilead Sciences late Wednesday posted third-quarter earnings and sales that beat views, but the Covid-19 treatment maker lowered its outlook; GILD stock hit seven-year lows in regular trading. The post Gilead Sciences Posts Earnings Beat But Lowers Outlook, After GILD Stock Hits Seven-Year Lows appeared first on Investor's Business Daily.

Gilead Sciences Posts Earnings Beat But Lowers Outlook, After GILD Stock Hits Seven-Year Lows

Shares of Gilead Sciences (NASDAQ:GILD) rose 1.6% after the company reported Q3 results. Quarterly Results Earnings per share rose 20.57% over the past year to $2.11, which beat the estimate of $1.95.

Recap: Gilead Sciences Q3 Earnings

In the first quarter of sales of its COVID-19 antiviral drug, Gilead Sciences Inc. produced better profit and sales than expected, sending its beleaguered shares higher in late trading.

Fast start for coronavirus drug boosts Gilead earnings, sends stock higher in late trading

Gilead Sciences Inc reported a 17% rise in quarterly revenue on Wednesday, helped by sales of its antiviral drug remdesivir, the first and only treatment approved in the United States for patients hospitalized with COVID-19.

Gilead quarterly revenue rises 17% on remdesivir sales

FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the company's Board of Directors has declared a cash dividend of $0.68 per share of common stock for the fourth quarter of 2020. The dividend is payable on December 30, 2020, to stockholders of record at the close of business on December 15, 2020. Future dividends will be subject to Board approval. About Gilead Sciences Gilead Sciences, Inc. is a research-based biopharmaceutical company that discover

Gilead Sciences Announces Fourth Quarter 2020 Dividend

FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) announced today its results of operations for the third quarter 2020. “The recent acquisition of Immunomedics has effectively transformed Gilead's growth story. Building on the foundation of our strong core business, which proved its durability once again this quarter, we have now significant opportunity to drive additional growth at an accelerated pace,” said Daniel O'Day, Chairman and Chief Executive Officer, Gilead Sc

Gilead Sciences Announces Third Quarter 2020 Financial Results

Tao Value recently released its Q3 2020 Investor Letter, a copy of which you can download here. The fund posted a return of 7.08% for the quarter, underperforming its benchmark, the MSCI All Country World Index (ACWI) which returned 8.41% in the same quarter. You should check out Tao Value's top 5 stock picks for investors to buy right now, which could be the biggest winners of this year.

Why Gilead Sciences (GILD) Stock is a Compelling Investment Case

Despite its robust HIV portfolio, promising COVID-19 therapeutic, and solid dividend yield, this stock is still a bargain today.

Here's Why Gilead Sciences Is More Than Just a COVID-19 Play

Immunomedics

The company's recent acquisition at a lofty premium looks similar to other Gilead deals. That could mean one of two things for investors.

Should You Buy Immunomedics Before the Gilead Sciences Acquisition Closes?

Alexion Pharma

Biogen

Moderna

Regeneron Pharmaceuticals

Vertex Pharmaceuticals

The short interest data are out for October 15, the most recent settlement date. Generally speaking, companies within the biotech industry are considered a riskier group of stocks, with big potential upside and big potential downside.

Major Biotechs Have Short Sellers Looking Both Ways

Eli Lilly

The feds have stopped a clinical trial of two coronavirus treatments after determining the combination of drugs wasn't helping hospitalized patients. The study aimed to evaluate whether Eli Lilly and Co.'s antibody treatment was effective in people hospitalized for COVID-19 who were also receiving remdesivir, the antiviral drug developed by Gilead Sciences.

Feds end study trying to treat COVID-19 with Eli Lilly antibody, remdesivir

BioNTech SE

Pfizer

It could translate to good news for biotechs with COVID-19 therapies.

Here's the Biggest Misconception About Coronavirus Vaccines

General Dynamics

Altria

AT&T

I have added to my taxable account 45.9168 shares at $27.00 for a total investment of $1,239.75 in AT&T Inc. I have added to my taxable account 17.7940 shares at $39.33 for a total investment of $699.83 in Altria Group, Inc.

Recent Stock Purchase October 2020

The first approval of a COVID-19 drug in the US wasn't quite a cause for celebration. US regulators approved the virus-fighting drug remdesivir on Thursday, greenlighting its use in hospitalized patients. The US Food and Drug Administration had given an emergency OK for the drug's use in May.

Gilead is set to sell billions of dollars of a coronavirus drug that's far from 'amazing' after the US approved remdesivir to treat COVID-19

Inovio Pharmaceuticals

Clinical trial delays and skeptical scientists spell trouble for these stocks.

2 Coronavirus Stocks to Avoid This Month

Horizon Kinetics Spac Active ETF

Twilio

Snap

Twilio, Gilead Sciences, Snap and Spartan Energy Acquisition are our top stock trades to watch on Monday. And here's why.

4 Top Stock Trades for Monday: TWLO, SNAP, SPAQ, GILD

The drug, now called Veklury, is the first coronavirus treatment to receive full approval from the Food and Drug Administration.

3 important things to know about remdevisir, the first FDA-approved coronavirus treatment

Gilead Sciences, Inc. (NASDAQ: GILD) is the first company to receive full FDA approval for a COVID-19 treatment. The Gilead Analyst: Raymond James analyst Steven Seedhouse has a Market Perform rating on Gilead shares.

Gilead Analyst: FDA's Remdesivir Label A Best Case Scenario For Biopharma

The Food and Drug Administration's decision to grant a full approval to Gilead Sciences Inc.'s remdesivir is raising questions about the broader value of a drug that has been praised for being ‘first' but may only provide limited clinical benefits.

Doctors question FDA approval of Gilead's COVID-19 treatment and say it has limited benefits

Want to know what the big remdesivir approval actually means for Gilead stock? Here's everything investors need to understand.

Gilead Stock: 12 Things for Investors to Know About Remdesivir Approval

Gilead Sciences Inc. (NASDAQ: GILD) is the first company to cross the finish line for regulatory approval in the fight against the coronavirus.

Gilead Is the First COVID-19 Stock to Win FDA Approval

FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today announced the completion of the previously announced transaction to acquire Immunomedics, Inc. (Nasdaq: IMMU) for approximately $21 billion in the aggregate. “We are very pleased to reach today's milestone and to welcome the talented Immunomedics team to the Gilead family. There is a lot of important work ahead of us to deliver on the vast potential that Trodelvy offers for patients with cancer,” said Daniel O'Day,

News for Gilead Sciences Stock (GILD)